Membro del progetto di A3-year open label, non comparative extension to a randomized, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (20 to 60 mg/kg/day) in Beta-thalassemia patients with transfusional hemosiderosis(2004 Jan).

Membro del progetto di A3-year open label, non comparative extension to a randomized, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (20 to 60 mg/kg/day) in Beta-thalassemia patients with transfusional hemosiderosis

2004

Novartis/ Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena- Fondazione IRCCS di Natura Pubblica
Activity
Membro del progetto di A3-year open label, non comparative extension to a randomized, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (20 to 60 mg/kg/day) in Beta-thalassemia patients with transfusional hemosiderosis(2004 Jan).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/29441
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact